Search
Daratumumab
go.drugbank.com/drugs/DB09331ApprovedInvestigational[L13290] It is approved for the treatment of multiple myeloma as monotherapy or combination therapy and light chain (AL) amyloidosis in combination with other drugs. … In July 2024, it was further approved in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for induction and consolidation therapy in newly diagnosed, transplant-eligible patients.
Products: Darzalex IV, DARZALEX CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/20MLDual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide
go.drugbank.com/bio_entities/BE0001300TargetHumansMay act as a B-cell-associated adapter that regulates B-cell antigen receptor (BCR)-signaling downstream of PI3K
Polypeptides: Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositideIfosfamide
go.drugbank.com/drugs/DB01181ApprovedInvestigationalIfosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.
Products: IFO-cell N 1000; Solution for Infusion (1000mg per vial), IFO-CELL N 1000Mitomycin
go.drugbank.com/drugs/DB00305ApprovedInvestigational[A193419] Mitomycin's cross-linking activity has resulted in its approval for the treatment of a variety of cancers - the most recent of which is an April 2020 approval for its use in low-grade Upper … Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.
Categories: Compounds used in a research, industrial, or household settingSynonyms: Mitomycin-XYeast
go.drugbank.com/drugs/DB11017ApprovedYeast allergenic extract is used in allergenic testing.
Categories: Non-Standardized Food Allergenic Extract, Non-Standardized Fungal Allergenic ExtractProducts: REFLOR 250 MG LIYOFILIZE TOZ ICEREN SASE, 10 ADET, REFLOR 250 MG LIYOFILIZE TOZ ICEREN SASE, 20 ADETSpectinomycin
go.drugbank.com/drugs/DB00919ApprovedVet approvedWithdrawnAn antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of gonorrhea.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseProducts: TROBICIN FOR INJECTION 2 g/vial, Trobicin Inj 400mg/mlCefoxitin
go.drugbank.com/drugs/DB01331ApprovedInvestigationalCefoxitin is a semi-synthetic, broad-spectrum cepha antibiotic for intravenous administration. It is derived from cephamycin C, which is produced by <i>Streptomyces lactamdurans</i>.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseProducts: Cefoxitin for Injection, Cefoxitin for Injection USPBismuth subsalicylate
go.drugbank.com/drugs/DB01294ApprovedVet approved[A230733] Bismuth subsalicylate has been around for over 100 years: it was originally developed in 1901 for hygienic use and sanitation for cholera infection. … Exhibiting antibacterial and gastroprotective properties, bismuth subsalicylate is an insoluble salt of [salicylic acid] linked to trivalent [bismuth cation].
Mixtures: Pepto-Bismol and Pepto-Bismol To Go, Pepto-Bismol and Pepto-Bismol To GoProducts: Rx Act Stomach Relief, PEPTIMAX FSRNeostigmine
go.drugbank.com/drugs/DB01400ApprovedInvestigationalVet approvedA cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. … Neostigmine, unlike physostigmine, does not cross the blood-brain barrier.
Synonyms: 3-Trimethylammoniumphenyl N,N-dimethylcarbamateProducts: NEOSTIGMIN 0,5 MG/ML IM/IV/SC ENJEKSİYONLUK ÇÖZELTİ, , 6 ADET, NEOSTİGMİN 0,5 MG/ML IM/IV/SC ENJEKSİYONLUK ÇÖZELTİ, , 50 ADETEdaravone
go.drugbank.com/drugs/DB12243ApprovedInvestigationalHowever, the drug manufacturer, Mitsubishi Tanabe Pharma, withdrew the Marketing Authorization Application (MAA) for edaravone from the European market on May 24, 2019, in response to the request made … [L44007] It was later approved for the treatment of amyotrophic lateral sclerosis (ALS) in Japan and South Korea in 2015, followed by the FDA approval in May 2017 [L41810] and Health Canada approval in
Categories: Compounds used in a research, industrial, or household settingProducts: RADICAVA™ IV Concentrate Solution for Infusion 30mg/20mL